Table 3.
Association between subject characteristics and neurologic worsening post- COVID-19.
| Neurologic worsening post- COVID-19 | No neurologic worsening post- COVID-19 | p-value | |
|---|---|---|---|
| N | 41 | 62 | |
| Age, years (SD) | 48.2 (11.9) | 49.2 (12.3) | 0.701 |
| Female; n (%) | 32 (78.0) | 47 (75.8) | 0.980 |
| Disease type (n) | 0.166 | ||
| RRMS | 24 | 44 | |
| CIS | 2 | 0 | |
| SPMS | 7 | 13 | |
| PPMS | 4 | 2 | |
| Related disorders | 4 | 3 | |
| DMT type (n) | 0.071 | ||
| None | 11 | 8 | |
| Teriflunomide | 1 | 3 | |
| Fingolimod | 0 | 9 | |
| Anti-CD20 | 23 | 27 | |
| Glatiramer | 2 | 7 | |
| Interferon-beta | 0 | 1 | |
| Dimethyl fumarate | 2 | 3 | |
| Natalizumab | 0 | 3 | |
| Other | 2 | 1 | |
| Disease duration, years (SD) | 12.5 (10.7) | 12.5 (8.7) | 0.969 |
| EDSS median (range) | 2.5 (0, 8.5) | 2 (0, 8.5) | 0.978 |
| Non-white; n (%) | 13 (31.7) | 16 (25.8) | 0.669 |
| Treatment for COVID-19; n (%)⁎ | 17 (45.0) | 9 (15.5) | 0.006 |
| Vitamin D use; n (%)⁎⁎ | 29 (74.4) | 54 (87.1) | 0.173 |
| Moderate/severe COVID-19; n (%)⁎⁎ | 18 (43.9) | 7 (11.7) | 0.001 |
| Recovered from COVID-19; n (%)⁎⁎⁎ | 27 (71.1) | 56 (90.3) | 0.027 |
Legend: For age and disease duration, the reported p-value is from a two-sample t-test. For EDSS, the reported p-value is from a Wilcoxon rank sum test. For the remaining variables, the reported p-value is from a chi-squared test.
⁎
: Five patients were missing COVID-19 treatment.
⁎⁎
: Two patients were missing vitamin D use and COVID-19 severity.
⁎⁎⁎
: Three patients were missing recovered from COVID-19.